

Coraline Dumenil

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3714436/publications.pdf>

Version: 2024-02-01

14
papers

665
citations

1163117

8
h-index

1199594

12
g-index

14
all docs

14
docs citations

14
times ranked

1454
citing authors

#	ARTICLE	IF	CITATIONS
1	Gene expression profile of high PD-L1 non-small cell lung cancers refractory to pembrolizumab. <i>Cancer Immunology, Immunotherapy</i> , 2022, 71, 2791-2799.	4.2	3
2	Baseline Hedgehog Pathway Activation and Increase of Plasma Wnt1 Protein Are Associated with Resistance to Immune Checkpoint Inhibitors in Advanced Non-Small-Cell Lung Cancer. <i>Cancers</i> , 2021, 13, 1107.	3.7	16
3	Plasma Biomarkers Screening by Multiplex ELISA Assay in Patients with Advanced Non-Small Cell Lung Cancer Treated with Immune Checkpoint Inhibitors. <i>Cancers</i> , 2021, 13, 97.	3.7	6
4	Sequential ctDNA whole-exome sequencing in advanced lung adenocarcinoma with initial durable tumor response on immune checkpoint inhibitor and late progression. , 2020, 8, e000527.		24
5	Role of antibiotic use, plasma citrulline and blood microbiome in advanced non-small cell lung cancer patients treated with nivolumab. , 2019, 7, 176.		62
6	Positive plasma cotinine during platinum-based chemotherapy is associated with poor response rate in advanced non-small cell lung cancer patients. <i>PLoS ONE</i> , 2019, 14, e0219080.	2.5	1
7	Plasma Biomarkers and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer: New Tools for Better Patient Selection?. <i>Cancers</i> , 2019, 11, 1269.	3.7	25
8	Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer. <i>Oncolmunology</i> , 2018, 7, e1424675.	4.6	66
9	Predictive role of plasmatic biomarkers in advanced non-small cell lung cancer treated by nivolumab. <i>Oncolmunology</i> , 2018, 7, e1452581.	4.6	115
10	Combination of Crizotinib and Osimertinib or Erlotinib Might Overcome MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitor in EGFR-Mutated Adenocarcinoma. <i>Journal of Thoracic Oncology</i> , 2018, 13, e232-e234.	1.1	21
11	Clinical factors associated with early progression and grade 3-4 toxicity in patients with advanced non-small-cell lung cancers treated with nivolumab. <i>PLoS ONE</i> , 2018, 13, e0195945.	2.5	46
12	Epigenetic prediction of response to anti-PD-1 treatment in non-small-cell lung cancer: a multicentre, retrospective analysis. <i>Lancet Respiratory Medicine</i> , 2018, 6, 771-781.	10.7	167
13	Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. <i>European Journal of Cancer</i> , 2017, 78, 16-23.	2.8	108
14	Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration. <i>Oncotarget</i> , 2017, 8, 109818-109835.	1.8	5